- Home
- GMAB vs REG Comparison
GMAB vs REG Comparison
Compare GMAB & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- REG
- Stock Information
- Founded
- GMAB 1999
- REG 1963
- Country
- GMAB Denmark
- REG United States
- Employees
- GMAB N/A
- REG N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- REG Real Estate Investment Trusts
- Sector
- GMAB Health Care
- REG Real Estate
- Exchange
- GMAB Nasdaq
- REG Nasdaq
- Market Cap
- GMAB 13.7B
- REG 12.9B
- IPO Year
- GMAB N/A
- REG 1993
- Fundamental
- Price
- GMAB $21.45
- REG $69.16
- Analyst Decision
- GMAB Buy
- REG Buy
- Analyst Count
- GMAB 8
- REG 13
- Target Price
- GMAB $37.80
- REG $78.00
- AVG Volume (30 Days)
- GMAB 1.6M
- REG 1.2M
- Earning Date
- GMAB 08-07-2025
- REG 07-29-2025
- Dividend Yield
- GMAB N/A
- REG 4.07%
- EPS Growth
- GMAB 276.80
- REG 2.69
- EPS
- GMAB 18.36
- REG 2.11
- Revenue
- GMAB $3,230,902,140.00
- REG $1,522,885,000.00
- Revenue This Year
- GMAB $747.74
- REG $1.44
- Revenue Next Year
- GMAB $14.81
- REG $4.13
- P/E Ratio
- GMAB $11.66
- REG $32.88
- Revenue Growth
- GMAB 25.43
- REG 7.57
- 52 Week Low
- GMAB $17.24
- REG $62.92
- 52 Week High
- GMAB $28.56
- REG $78.18
- Technical
- Relative Strength Index (RSI)
- GMAB 53.47
- REG 38.43
- Support Level
- GMAB $20.23
- REG $69.93
- Resistance Level
- GMAB $21.90
- REG $70.03
- Average True Range (ATR)
- GMAB 0.35
- REG 1.19
- MACD
- GMAB 0.06
- REG -0.16
- Stochastic Oscillator
- GMAB 73.52
- REG 14.66
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 482 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.